Page 12 - Gamida Cell News Today

/PRNewswire/ -- DelveInsights Paroxysmal Nocturnal Hemoglobinuria Market Insights report includes a comprehensive understanding of current treatment...

Treatments for blood cancer and rare diseases are the target markets, but investors are well aware of the challenges that await after approval is received.

In a report released today, Gil Blum from Needham reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price...

14.11.2022 - Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ...

Gamida Cell Ltd. (NASDAQ:NASDAQ:GMDA) Q3 2022 Results Conference Call November 14, 2022 8:00 AM ETCompany ParticipantsHeather DiVecchia - Director of IR & Corporate...

Citeline shares insights on a longer-term outlook at some key late-stage drugs projected to hit the market in 2023

(RTTNews) - Gamida Cell Ltd. (GMDA) reported long term follow-up data and health-related quality of life scores of patients treated with omidubice...

Gamida Cell Ltd. GMDA, the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other se

12.09.2022 - Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the presentation of data supporting the potential of omidubicel ... Seite 1

- Nicole Paulk, an expert in gene therapy, joins GRObio’s Scientific Advisory Board (SAB) as It Advances its ProGly™ Immunomodulation Chemistries into Gene Therapy -BOSTON--(BUSINESS WIRE)--GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging synthetic biology to expand the amino acid alphab...